Buspar
Result: $90 million settlement
Year: 2003
In re Buspirone Antitrust Litigation
In November 2003, Lieff Cabraser obtained a $90 million cash settlement for individual consumers, consumer organizations, and third party payers that purchased BuSpar, a drug prescribed to alleviate symptoms of anxiety.
Plaintiffs alleged that Bristol-Myers Squibb Co. (BMS), Danbury Pharmacal, Inc., Watson Pharmaceuticals, Inc. and Watson Pharma, Inc. entered into an unlawful agreement in restraint of trade under which BMS paid a potential generic manufacturer of BuSpar to drop its challenge to BMS’ patent and refrain from entering the market.
Lieff Cabraser served as Plaintiffs’ Co-Lead Counsel.
Civil Litigation News
Mark Chalos Selected as Co-Lead Counsel for Plaintiffs in Generac Solar Power Systems Marketing Practice and Products Liability Litigation
The Generac Solar Energy Systems litigation focuses on allegations that energy tech giant Generac’s PWRECell System components are defective and potentially dangerous
Sarah London Testifies Before the CA State Assembly in Support of Bill to Stop Corporate Arbitration Abuse in California
On June 13, 2023, Lieff Cabraser partner Sarah London testified before the California State Assembly in support of SB 365. The bill,
Lieff Cabraser Announces Historic $235M Comprehensive Settlement with Altria in National JUUL Youth E-Cigarette Predatory Advertising, Addiction and Injury Cases
Unprecedented in scope, speed, and significance, the global settlement, reached just after plaintiffs concluded their case in the bellwether trial in San
